Chemoreduction with cyclophosphamide controls retinoblastoma progression

Chemoreduction with cyclophosphamide controlled progression of retinoblastoma while preventing the need for enucleation and external beam radiotherapy, a study found.The retrospective study included 56 eyes of 40 patients with retinoblastoma who underwent six cycles of intravenous cyclophosphamide, vincristine, etoposide and carboplatin. Cycles were every 21 days, and mean follow-up was 101 months.

Full Story →